New service enables identification of bispecific antibody candidates accelerating drug development.

New comprehensive biomarker panels equip physicians with clinically actionable insights for earlier, more accurate diagnosis.

Strategic activation unites best-in-class technology with end-to-end development solutions to optimize therapeutic development process.

Xavo, proudly announces Plexium as its latest esteemed client. - “We are thrilled to welcome Plexium to the Xavo family. The collaboration between the two companies marks a significant milestone in Xavo’s journey.

The teams aim to redefine plasmid sequencing with nanopore technology and global accessibility.

Touchlight, announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products.

Strategic collaborations in molecular residual disease monitoring of cancer and product launches in ddPCR portfolio advance corporate strategy in H1 2024.

Cresset, announces the release of V9 - the latest version of its Flare platform for ligand-based and structure-based design, which includes a full integration of Spark™, Cresset’s bioisostere replacement solution.

Highly accurate long-read sequencing data will be used at Novogene’s new lab in Munich, supporting customers across a network of leading research institutions.

Proofig AI’s new detector of fabrication tool to help preserve research integrity.